Aspirin for covid early treatment

Published: October 12, 2020
Share on: Twitter / Facebook

Note: Patients are asked to consult a doctor.

The SPR collaboration has added aspirin to its covid early treatment protocol. New studies have confirmed a strong antiplatelet and anticoagulant effect of aspirin in covid patients (i.e. reducing platelet hyper-reactivity, see figure below), which may help prevent major covid complications such as thrombosis, lung embolism and strokes in high-risk patients.

As an additional effect, intermediate-dose aspirin may also reduce or suppress the signature covid dry cough. This is because the covid dry cough appears to be an ACEI-induced cough mediated by prostaglandins, and aspirin is well known to inhibit prostaglandins and suppress ACEI cough.

The SPR collaboration once again strongly recommends that health authorities implement large-scale early or prophylactic treatment protocols for high-risk covid patients in order to prevent disease progression and avoid unnecessary hospitalizations and complications.

Study: Platelet gene expression and function in patients with COVID-19 (ASH Blood)

Effect of aspirin on platelet hyper-reactivity and aggregation in covid patients:
Left: platelet hyperreactivity and aggregation in healthy donors (HD, red) and untreated covid patients (green); right: platelet aggregation in healthy donors and in covid patient blood treated with aspirin (Manne et al, supplement 4)

See also

Share on: Twitter / Facebook

Up ↑